Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Dupilumab has recently demonstrated high efficacy and good safety profile in the treatment of
moderate-to-severe atopic dermatitis. There is a crucial need of developing new treatment
options in Chronic hand eczema refractory to topical therapy. Investigators hypothesise that
Dupilumab will also have high efficacy and good safety profile in the treatment of moderate
to severe Chronic hand eczema refractory to highly potent topical corticosteroids.